Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis

NCT06073119 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06073119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06073119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study of Efficacy and Safety of SAR441566 in Adults With Moderate to Severe Plaque Psoriasis
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
October 26, 2023
Completion date
December 11, 2024
Enrollment
221 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis